Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020;22(11):E911-918. doi:
10.1001/amajethics.2020.911.
The ethical questions surrounding the recruitment of patients for clinical trials become more complicated when the recruiting physicians receive financial benefits for each patient enrolled.
The ethical questions surrounding the recruitment of patients for clinical trials become more complicated when the recruiting physicians receive financial benefits for each patient enrolled.
Dr Brady J. Heward joins Ethics Talk to discuss his article, coauthored with Drs Amy M. Yule and Peter R. Jackson: “How Should Harm Reduction Strategies Differ for Adolescents and Adults?”
The authors of a recent journal article believe that most doctors and clinical trial sponsors would not object to changes in regulations requiring doctors to disclose financial incentives to their patients.